SCHEDULE: Ikarian Capital Discloses 2.0% Stake in Aethlon Medical
Beneficial Ownership Report
Ikarian Capital, LLC and Neil Shahrestani have reported a 2.0% beneficial ownership stake in Aethlon Medical, Inc., totaling 15,366 shares.
Summary
- Ikarian Capital, LLC and Neil Shahrestani jointly reported beneficial ownership of 15,366 shares of Aethlon Medical, Inc. common stock.
- This represents a 2.0% stake in the company, based on 761,318 shares outstanding as of November 10, 2025.
- The shares are held by Ikarian Healthcare Master Fund, L.P. and certain separate managed accounts, for which Ikarian Capital serves as investment manager or sub-adviser.
- Neil Shahrestani indirectly controls Ikarian Capital and is therefore deemed to indirectly beneficially own the securities.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The filing is a standard beneficial ownership report (Schedule 13G Amendment No. 1) disclosing a 2.0% stake in Aethlon Medical, Inc. by Ikarian Capital, LLC and Neil Shahrestani. It indicates a continued, non-activist investment by a specialized fund, which is a neutral event in terms of company performance or outlook.
Positives
- A significant institutional investor, Ikarian Capital, maintains a position in Aethlon Medical, indicating continued interest in the company.
Future Outlook
na
Industry Context
This filing indicates an investment by a healthcare-focused fund in Aethlon Medical, a company typically associated with medical device or biotechnology sectors. Such investments are common for specialized funds seeking exposure to specific industry innovations or growth opportunities.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can offer some level of confidence or insight into institutional interest. However, the 2.0% stake is not large enough to suggest control or significant influence over corporate decisions.
Key Dates
| Date | Description |
|---|---|
| 2025-02-14 | Date of the original Schedule 13G filing by the Reporting Persons with the SEC, to which a Joint Filing Agreement is incorporated by reference. |
| 2025-09-30 | Date of event requiring the filing of this statement. |
| 2025-11-10 | Date as of which 761,318 shares of Common Stock of the Issuer were outstanding, as disclosed in the Issuer's quarterly report on Form 10-Q. |
| 2025-11-12 | Date the Issuer's quarterly report on Form 10-Q for the period ended September 30, 2025, was filed with the SEC. |
| 2025-11-14 | Date of signing of the Schedule 13G by Ikarian Capital, LLC and Neil Shahrestani. |
Keywords
Aethlon Medical, Ikarian Capital, Neil Shahrestani, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Healthcare, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.